Vaxcyte to Present at Upcoming Investor Conferences
31 Octubre 2023 - 2:05PM
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases, today announced that
Company management will participate in fireside chats and host
one-on-one meetings at the following investor conferences:
Guggenheim 5th Annual
Inflammation & Immunology ConferenceNovember
6-7, 2023
- Fireside Chat will take place live on Tuesday, November 7 at
11:10AM ET
Jefferies London Healthcare
ConferenceNovember 14-16, 2023
- Fireside Chat will take place live on Tuesday, November 14 at
8:00AM GMT / 3:00AM ET
Evercore ISI 6th
Annual HealthCONx ConferenceNovember
28-30, 2023
- Fireside Chat will take place live on Tuesday, November 28 at
8:20AM ET
The live webcasts of these fireside chats can be accessed
through the Investors & Media section of the Company’s website
at http://investors.vaxcyte.com. A replay of the webcasts will be
available for approximately 30 days following each respective
conference.
About Vaxcyte Vaxcyte is a vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases. The Company is
developing broad-spectrum conjugate and novel protein vaccines to
prevent or treat bacterial infectious diseases. Vaxcyte’s lead
candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing
pneumococcal conjugate vaccine (PCV) being developed for the
prevention of invasive pneumococcal disease and is poised to move
into late-stage development. VAX-31, which will be the
broadest-spectrum PCV candidate to enter the clinic, is a follow-on
candidate to VAX-24 and part of the Company’s PCV franchise.
Vaxcyte is re-engineering the way highly complex vaccines are
made through modern synthetic techniques, including advanced
chemistry and the XpressCF™ cell-free protein synthesis platform,
exclusively licensed from Sutro Biopharma, Inc. Unlike conventional
cell-based approaches, the Company’s system for producing
difficult-to-make proteins and antigens is intended to accelerate
its ability to efficiently create and deliver high-fidelity
vaccines with enhanced immunological benefits. Vaxcyte’s pipeline
also includes VAX-A1, a prophylactic vaccine candidate designed to
prevent Group A Strep infections; VAX-PG, a therapeutic vaccine
candidate designed to slow or stop the progression of periodontal
disease; and VAX-GI, a vaccine program designed to prevent
Shigella. Vaxcyte is driven to eradicate or treat invasive
bacterial infections, which have serious and costly health
consequences when left unchecked. For more information, visit
www.vaxcyte.com.
Contacts:Jennifer Zibuda, Senior Director,
Investor RelationsVaxcyte,
Inc.860-729-8902investors@vaxcyte.com
Vaxcyte (NASDAQ:PCVX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Vaxcyte (NASDAQ:PCVX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024